---
document_datetime: 2025-12-02 05:09:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tizveni.html
document_name: tizveni.html
version: success
processing_time: 0.0977105
conversion_datetime: 2025-12-29 22:08:40.60219
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tizveni

[RSS](/en/individual-human-medicine.xml/232649)

##### Withdrawn

This medicine's authorisation has been withdrawn

tislelizumab Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 5 July 2024, the European Commission withdrew the marketing authorisation for Tizveni (tislelizumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Beigene Ireland Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Tizveni was granted marketing authorisation in the EU on 19 April 2024 for the treatment of locally advanced or metastatic non-small cell lung cancer in adults. The marketing authorisation was initially valid for a 5-year period. Tizveni is an identical product to Tevimbra, which is authorised in the EU to treat locally advanced or metastatic non-small cell lung cancer and unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma in adults.

The European Public Assessment Report (EPAR) for Tizveni is updated to indicate that the marketing authorisation is no longer valid.

Tizveni : EPAR - Medicine overview

Reference Number: EMA/87936/2024

English (EN) (687.32 KB - PDF)

**First published:** 23/05/2024

**Last updated:** 02/08/2024

[View](/en/documents/overview/tizveni-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-662)

български (BG) (835.69 KB - PDF)

**First published:**

01/08/2024

[View](/bg/documents/overview/tizveni-epar-medicine-overview_bg.pdf)

español (ES) (740.64 KB - PDF)

**First published:**

01/08/2024

[View](/es/documents/overview/tizveni-epar-medicine-overview_es.pdf)

čeština (CS) (818.38 KB - PDF)

**First published:**

01/08/2024

[View](/cs/documents/overview/tizveni-epar-medicine-overview_cs.pdf)

dansk (DA) (739.3 KB - PDF)

**First published:**

01/08/2024

[View](/da/documents/overview/tizveni-epar-medicine-overview_da.pdf)

Deutsch (DE) (745.51 KB - PDF)

**First published:**

01/08/2024

[View](/de/documents/overview/tizveni-epar-medicine-overview_de.pdf)

eesti keel (ET) (766.9 KB - PDF)

**First published:**

01/08/2024

[View](/et/documents/overview/tizveni-epar-medicine-overview_et.pdf)

ελληνικά (EL) (844.22 KB - PDF)

**First published:**

01/08/2024

[View](/el/documents/overview/tizveni-epar-medicine-overview_el.pdf)

français (FR) (744.44 KB - PDF)

**First published:**

01/08/2024

[View](/fr/documents/overview/tizveni-epar-medicine-overview_fr.pdf)

hrvatski (HR) (766.34 KB - PDF)

**First published:**

01/08/2024

[View](/hr/documents/overview/tizveni-epar-medicine-overview_hr.pdf)

italiano (IT) (738.04 KB - PDF)

**First published:**

01/08/2024

[View](/it/documents/overview/tizveni-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (825.37 KB - PDF)

**First published:**

01/08/2024

[View](/lv/documents/overview/tizveni-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (767.07 KB - PDF)

**First published:**

01/08/2024

[View](/lt/documents/overview/tizveni-epar-medicine-overview_lt.pdf)

magyar (HU) (816.79 KB - PDF)

**First published:**

01/08/2024

[View](/hu/documents/overview/tizveni-epar-medicine-overview_hu.pdf)

Malti (MT) (820.74 KB - PDF)

**First published:**

01/08/2024

[View](/mt/documents/overview/tizveni-epar-medicine-overview_mt.pdf)

Nederlands (NL) (740.66 KB - PDF)

**First published:**

01/08/2024

[View](/nl/documents/overview/tizveni-epar-medicine-overview_nl.pdf)

polski (PL) (815.57 KB - PDF)

**First published:**

01/08/2024

[View](/pl/documents/overview/tizveni-epar-medicine-overview_pl.pdf)

português (PT) (704.83 KB - PDF)

**First published:**

01/08/2024

[View](/pt/documents/overview/tizveni-epar-medicine-overview_pt.pdf)

română (RO) (768 KB - PDF)

**First published:**

01/08/2024

[View](/ro/documents/overview/tizveni-epar-medicine-overview_ro.pdf)

slovenčina (SK) (1.43 MB - PDF)

**First published:**

01/08/2024

[View](/sk/documents/overview/tizveni-epar-medicine-overview_sk.pdf)

slovenščina (SL) (811.67 KB - PDF)

**First published:**

01/08/2024

[View](/sl/documents/overview/tizveni-epar-medicine-overview_sl.pdf)

Suomi (FI) (738.59 KB - PDF)

**First published:**

01/08/2024

[View](/fi/documents/overview/tizveni-epar-medicine-overview_fi.pdf)

svenska (SV) (739.89 KB - PDF)

**First published:**

01/08/2024

[View](/sv/documents/overview/tizveni-epar-medicine-overview_sv.pdf)

Tizveni : EPAR - Risk management plan

English (EN) (1.48 MB - PDF)

**First published:** 23/05/2024

**Last updated:** 02/08/2024

[View](/en/documents/rmp/tizveni-epar-risk-management-plan_en.pdf)

## Product information

Tizveni : EPAR - Product information

English (EN) (1.24 MB - PDF)

**First published:** 23/05/2024

**Last updated:** 02/08/2024

[View](/en/documents/product-information/tizveni-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-698)

български (BG) (2.8 MB - PDF)

**First published:**

01/08/2024

[View](/bg/documents/product-information/tizveni-epar-product-information_bg.pdf)

español (ES) (1.5 MB - PDF)

**First published:**

01/08/2024

[View](/es/documents/product-information/tizveni-epar-product-information_es.pdf)

čeština (CS) (2.31 MB - PDF)

**First published:**

01/08/2024

[View](/cs/documents/product-information/tizveni-epar-product-information_cs.pdf)

dansk (DA) (1.58 MB - PDF)

**First published:**

01/08/2024

[View](/da/documents/product-information/tizveni-epar-product-information_da.pdf)

Deutsch (DE) (1.64 MB - PDF)

**First published:**

01/08/2024

[View](/de/documents/product-information/tizveni-epar-product-information_de.pdf)

eesti keel (ET) (1.51 MB - PDF)

**First published:**

01/08/2024

[View](/et/documents/product-information/tizveni-epar-product-information_et.pdf)

ελληνικά (EL) (3.09 MB - PDF)

**First published:**

01/08/2024

[View](/el/documents/product-information/tizveni-epar-product-information_el.pdf)

français (FR) (1.57 MB - PDF)

**First published:**

01/08/2024

[View](/fr/documents/product-information/tizveni-epar-product-information_fr.pdf)

hrvatski (HR) (1.56 MB - PDF)

**First published:**

01/08/2024

[View](/hr/documents/product-information/tizveni-epar-product-information_hr.pdf)

íslenska (IS) (1.49 MB - PDF)

**First published:**

01/08/2024

[View](/is/documents/product-information/tizveni-epar-product-information_is.pdf)

italiano (IT) (1.55 MB - PDF)

**First published:**

01/08/2024

[View](/it/documents/product-information/tizveni-epar-product-information_it.pdf)

latviešu valoda (LV) (2.46 MB - PDF)

**First published:**

01/08/2024

[View](/lv/documents/product-information/tizveni-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.7 MB - PDF)

**First published:**

01/08/2024

[View](/lt/documents/product-information/tizveni-epar-product-information_lt.pdf)

magyar (HU) (2.45 MB - PDF)

**First published:**

01/08/2024

[View](/hu/documents/product-information/tizveni-epar-product-information_hu.pdf)

Malti (MT) (2.45 MB - PDF)

**First published:**

01/08/2024

[View](/mt/documents/product-information/tizveni-epar-product-information_mt.pdf)

Nederlands (NL) (1.46 MB - PDF)

**First published:**

01/08/2024

[View](/nl/documents/product-information/tizveni-epar-product-information_nl.pdf)

norsk (NO) (1.52 MB - PDF)

**First published:**

01/08/2024

[View](/no/documents/product-information/tizveni-epar-product-information_no.pdf)

polski (PL) (2.57 MB - PDF)

**First published:**

01/08/2024

[View](/pl/documents/product-information/tizveni-epar-product-information_pl.pdf)

português (PT) (1.43 MB - PDF)

**First published:**

01/08/2024

[View](/pt/documents/product-information/tizveni-epar-product-information_pt.pdf)

română (RO) (1.69 MB - PDF)

**First published:**

01/08/2024

[View](/ro/documents/product-information/tizveni-epar-product-information_ro.pdf)

slovenčina (SK) (2.4 MB - PDF)

**First published:**

01/08/2024

[View](/sk/documents/product-information/tizveni-epar-product-information_sk.pdf)

slovenščina (SL) (2.39 MB - PDF)

**First published:**

01/08/2024

[View](/sl/documents/product-information/tizveni-epar-product-information_sl.pdf)

Suomi (FI) (1.5 MB - PDF)

**First published:**

01/08/2024

[View](/fi/documents/product-information/tizveni-epar-product-information_fi.pdf)

svenska (SV) (1.49 MB - PDF)

**First published:**

01/08/2024

[View](/sv/documents/product-information/tizveni-epar-product-information_sv.pdf)

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tizveni : EPAR - All authorised presentations

English (EN) (608.58 KB - PDF)

**First published:** 23/05/2024

**Last updated:** 02/08/2024

[View](/en/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-845)

български (BG) (655.41 KB - PDF)

**First published:**

01/08/2024

[View](/bg/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_bg.pdf)

español (ES) (620.36 KB - PDF)

**First published:**

01/08/2024

[View](/es/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_es.pdf)

čeština (CS) (641.87 KB - PDF)

**First published:**

01/08/2024

[View](/cs/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (622.99 KB - PDF)

**First published:**

01/08/2024

[View](/da/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (626.56 KB - PDF)

**First published:**

01/08/2024

[View](/de/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (617.96 KB - PDF)

**First published:**

01/08/2024

[View](/et/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (651.49 KB - PDF)

**First published:**

01/08/2024

[View](/el/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_el.pdf)

français (FR) (621.32 KB - PDF)

**First published:**

01/08/2024

[View](/fr/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (624.8 KB - PDF)

**First published:**

01/08/2024

[View](/hr/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (625.54 KB - PDF)

**First published:**

01/08/2024

[View](/is/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_is.pdf)

italiano (IT) (619.53 KB - PDF)

**First published:**

01/08/2024

[View](/it/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (642.18 KB - PDF)

**First published:**

01/08/2024

[View](/lv/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (624.39 KB - PDF)

**First published:**

01/08/2024

[View](/lt/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (638.56 KB - PDF)

**First published:**

01/08/2024

[View](/hu/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (641.58 KB - PDF)

**First published:**

01/08/2024

[View](/mt/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (622.76 KB - PDF)

**First published:**

01/08/2024

[View](/nl/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (622.81 KB - PDF)

**First published:**

01/08/2024

[View](/no/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_no.pdf)

polski (PL) (642.06 KB - PDF)

**First published:**

01/08/2024

[View](/pl/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_pl.pdf)

português (PT) (624.42 KB - PDF)

**First published:**

01/08/2024

[View](/pt/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_pt.pdf)

română (RO) (626.82 KB - PDF)

**First published:**

01/08/2024

[View](/ro/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (1.2 MB - PDF)

**First published:**

01/08/2024

[View](/sk/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (637.17 KB - PDF)

**First published:**

01/08/2024

[View](/sl/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (621.64 KB - PDF)

**First published:**

01/08/2024

[View](/fi/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (623.88 KB - PDF)

**First published:**

01/08/2024

[View](/sv/documents/all-authorised-presentations/tizveni-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tizveni Active substance tislelizumab International non-proprietary name (INN) or common name tislelizumab Therapeutic area (MeSH) Carcinoma, Non-Small-Cell Lung Anatomical therapeutic chemical (ATC) code L01FF09

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Non-small cell lung cancer (NSCLC) Tizveni in combination with pemetrexed and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous non-small cell lung cancer whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have: • locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or • metastatic NSCLC. Tizveni in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of adult patients with squamous non-small cell lung cancer who have: • locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or • metastatic NSCLC. Tizveni as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab.

## Authorisation details

EMA product number EMEA/H/C/005542 Marketing authorisation holder

BeiGene Ireland Ltd

10 Earlsfort Terrace

Opinion adopted 22/02/2024 Marketing authorisation issued 19/04/2024

## Assessment history

## Initial marketing authorisation documents

Tizveni : EPAR - Public assessment report

Adopted

Reference Number: EMA/116407/2024

English (EN) (17.14 MB - PDF)

**First published:** 23/05/2024

**Last updated:** 02/08/2024

[View](/en/documents/assessment-report/tizveni-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tizveni

Adopted

Reference Number: EMA/CHMP/59203/2024

English (EN) (694.2 KB - PDF)

**First published:** 23/02/2024

**Last updated:** 02/08/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tizveni_en.pdf)

**This page was last updated on** 02/08/2024

## Share this page

[Back to top](#main-content)